Skip to content
Datasets/WCDT-MCRPC

Genomic Characterization of Metastatic Castration Resistant Prostate Cancer

MixedProject-curated
WCDTAvailable from GDC

101 metastatic castration-resistant prostate cancers with whole genome and RNA sequencing from metastatic biopsies - every case stage IV with documented progression, and no usable vital status.

Can it answer your research question?

3 of 6 supported
  • Overall survival

    Not supported

    Vital status is recorded for every case and informative for none; the cohort does carry recurrence-free interval and progression-free interval.API

  • Progression or recurrence

    Supported

    A time to event is derivable: recurrence-free interval, progression-free interval; progression_or_recurrence is informative for 100% of cases.API

  • Treatment response

    Limited

    disease_response is populated for 100% of cases.API

  • Which drug was given

    Not supported

    therapeutic_agents is recorded for no case in the harmonized records.API

  • Stage-adjusted modelling

    Supported

    ajcc_pathologic_stage is informative for 100% of cases.API

  • Analysis by race or ethnicity

    Supported

    Race is informative for 94% of cases.API

Judged from the repository’s own field completeness (thresholds). “Not measured” means we have not probed that field for this record, not that the data lack it.

At a glance

Every percentage is the repository’s own record of what is filled in
CasesAPI
101
Measurement types
4
1,900 files, 76 TB
Follow-upAPI
7.9 years
for 87 of 101 cases; recurrence-free interval, progression-free interval
Treatment responseAPI
Not recorded

SubjectCALC

Prostate

As filed by the repository

Adenomas and AdenocarcinomasProstate gland

Who is in the cohortAPI

A usable value“Not reported” or “unknown”No value recorded
  • Sex101 male
  • Race86 white · 5 black or african american · 4 asian · 6 unknown
  • Ethnicity94 not hispanic or latino · 7 unknown
  • Vital status101 unknown

Age at diagnosis

Median 71, middle half 66–76, range 45–90 years across 101 cases.

What was measured, and on how many

4 measurement types, 3 covering the whole cohort.

  • Bulk RNA sequencing99 of 101 · 98%
  • Whole genome sequencing101 of 101 · 100%
  • Copy Number Variation101 of 101 · 100%
  • Somatic Structural Variation101 of 101 · 100%
Platform, files and data levels
AssayPlatformFilesLevels
Bulk RNA sequencingAPIillumina891-
Whole genome sequencingAPIillumina1,009-
Copy Number VariationAPI-202-
Somatic Structural VariationAPI-205-
How complete all 29 clinical fields are - 11 informative for at least 80% of cases

A field counts as informative only when it holds a real value. “Not reported” blocks an analysis just as a missing field does. Fields marked 1:n can hold several records per case, so they show the share of cases with any record.

Informative - a usable valuePresent but uninformative - “not reported” or “unknown”Absent - no value recorded

Outcome

  • Progression or recurrenceAPI100%
  • Last known disease statusAPI100%
  • Vital statusAPI0%
  • Cause of deathAPI0%

Follow-up

  • Disease response at follow-upAPI100%
  • Progression at follow-upAPI100%
  • ECOG performance statusAPI0%

Treatment

  • Prior treatmentAPI0%
  • Treatment typeAPI0%
  • Treatment givenAPI0%
  • Therapeutic agentsAPI0%
  • Treatment outcomeAPI0%
  • Regimen or line of therapyAPI0%

Staging

  • AJCC pathologic stageAPI100%
  • AJCC clinical stageAPI0%

Diagnosis

  • Primary diagnosisAPI100%
  • Tissue or organ of originAPI100%
  • Prior malignancyAPI0%
  • Synchronous malignancyAPI0%

Pathology

  • Morphology (ICD-O)API100%
  • Tumor gradeAPI0%
  • Classification of tumorAPI0%

Demographics

  • Sex at birthAPI100%
  • RaceAPI94%
  • EthnicityAPI93%
  • Population groupAPI0%
  • Country of residenceAPI0%

Exposure

  • Tobacco smoking statusAPI0%
  • Alcohol historyAPI0%

Access

MixedSome components are open; others need approval.

Data Access Request through dbGaP using an eRA Commons account; institutional signing official approval required

Open components
200 open-access files
Controlled components
1,700 controlled-access files
Typical turnaround
days to a few weeks after signing official approval
License
NIH Genomic Data Sharing Policy terms
Citation requirement
Cite the dataset accession and the program's publication guidelines; see the GDC publication policy.

What it is good for

Written and checked by a reviewer, not generated from metadata.

  1. 1. What distinguishes the genome of metastatic castration-resistant prostate cancer from primary prostate cancer?

    Needs another datasetn ≈ 101HUMAN

    Whole genome sequencing on all 101 metastatic biopsies pairs naturally with TCGA-PRAD's 500 primary tumors in the same repository under the same harmonization. The contrast is the cohort's clearest use and does not depend on any outcome field.

    Statistical note: The two cohorts differ in sequencing strategy and processing era as well as in disease state, so treat platform as a confounder rather than assuming harmonization removed it.

    NeedsWhole genome sequencingCopy numberStructural variants

    A published example: PMID 31061129

  2. 2. Which transcriptional programs mark androgen receptor pathway independence and neuroendocrine transdifferentiation in treatment-resistant disease?

    Needs approved accessn ≈ 99HUMAN

    RNA sequencing on 99 metastatic biopsies is the right substrate for AR-signaling and neuroendocrine scoring, and metastatic tissue is where these phenotypes actually occur.

    Statistical note: Biopsy site varies across the cohort and contributes substantially to expression variance; include site as a covariate or stratify.

    NeedsBulk RNA sequencing
  3. 3. How do structural variants and genome rearrangement patterns differ between metastatic sites?

    Needs approved accessn ≈ 101HUMAN

    Structural variant calls exist for all 101 cases from whole genome rather than exome data, which is what makes rearrangement analysis credible here.

    NeedsStructural variantsWhole genome sequencing
  4. 4. Can expression or genomic features predict which metastatic biopsies come from patients with the most aggressive disease trajectory?

    Needs another datasetn ≈ 101HUMAN

    This is the question most people want the cohort for, and it is the one the harmonized records cannot support. It is listed here to be explicit that it requires outcome data obtained separately.

    Statistical note: Not answerable from the GDC records alone. Vital status is "unknown" for every case; outcomes must come from the marker publication's supplement or a dbGaP phenotype file.

    NeedsBulk RNA sequencingWhole genome sequencingOutcome data

What it cannot tell you

2 blocking

Written by a reviewer against the source, not inferred from what is missing.

BlockingMissing dataHUMAN

Vital status is populated for all 101 cases and informative for none - every value is "unknown". No overall survival endpoint exists in the harmonized records, despite a follow-up time being derivable for 87 of 101 cases with a median of 95 months.

Affects: Overall survival; Prognostic modeling; Outcome-anchored biomarker discovery

Mitigation: Outcome data are analyzed in the PNAS marker paper. Obtain them from its supplementary material or through dbGaP before planning any survival work.

BlockingTreatment contextHUMAN

No treatment field is populated: treatment type, therapeutic agents, treatment outcome and line of therapy are all empty. These are castration-resistant patients, so every one has had prior androgen deprivation and most will have had further systemic therapy, but which therapy and in what order is not recorded here.

Affects: Treatment-response analysis; Resistance mechanism attribution; Line-of-therapy stratification

Mitigation: Do not attribute molecular features to specific treatments using these records. The absence of treatment annotation in a treatment-defined cohort is the single most important thing to know before selecting it.

MajorStatistical powerHUMAN

101 cases limits subgroup analysis sharply. Any stratification by biopsy site, molecular subtype or genomic alteration leaves groups in the low tens.

Affects: Subgroup comparisons; Rare-variant association

Mitigation: Pre-specify a small number of hypotheses; treat subgroup results as exploratory.

MajorPopulation coverageHUMAN

86 of 101 cases are recorded as white and 5 as Black or African American, in a disease with pronounced incidence and mortality disparities affecting Black men.

Affects: Disparities research; Ancestry-stratified analysis

Mitigation: Do not use this cohort to characterise metastatic prostate cancer biology in Black patients; five cases cannot support it.

MajorAccess constraintHUMAN

1,700 of 1,900 files are controlled access.

Affects: Any sequence-level analysis

Mitigation: Budget several weeks for the dbGaP request.

Not appropriate for

  • Survival analysis or prognostic biomarker discovery from the GDC records. - Vital status is uninformative for all 101 cases.HUMAN
  • Attributing resistance mechanisms to particular drugs. - No treatment is recorded for any case, so drug attribution would be invented rather than observed.HUMAN
  • Studying prostate cancer disparities. - Five Black patients cannot support a disparities analysis.HUMAN

Who has used it

Articles that analyzed these data, counted separately from articles that only cited the paper. Only the first counts as reuse.

Analyzed the dataCALC2
27
accession in the methods section
Declared using it
24
named in a data availability statement
Cited the paper
1,206
attention to the publication, not reuse of the data
Against expectation
As expected or above
about 10 articles expected; index 1.38

What articles did with it

Only the last row counts as reuse. Where the accession appears in an article tells us what the authors did with the data.

  • Cited the paper1,206
  • Mentioned the dataset1
  • Accession found in text29
  • Declared using it24
  • Analyzed the data27

Against comparable datasets

27 articles analyzed these data. About 10 would be expected. The expectation comes from a model of size, age, breadth and access tier.

  • Analyzed it27
  • Expected~10
Well known, little used
The publication has 1,206 citations, about 45 for every article that analyzed the data. The finding travelled further than the resource did.
Reuse assessment
  • Reuse is within the expected range for comparable datasets (index +1.38).

Compared against 132 datasets in this corpus with a citable accession and sufficient metadata. See Methods for the model.

Original publication

Articles that analyzed the data

Examples, not the full list. 67 articles matching this dataset's accession search were retrieved and graded individually; these are the strongest of those.

Deep-review sample: author overlap and funding were checked only for the 10 articles listed here, not for every article examined. Of the 10 that analyzed the data, 3 of the 10 we could check had no author in common with the generating team, and 9 of the 10 we could check were themselves NCI-funded. These are sample counts, not population estimates.

Community examples

Share your example

Analyses someone ran on these data end to end, each with a receipt recording when it ran, against which packages and for how long.

beginner

Which classes of analysis do this cohort's clinical records actually support, and which are ruled out before I request access?

Audit whether this dataset can answer your question

CD2S workbooks · ran 21 Sept 2026
pythonabout a minuteexecuted
Required inputs
  • A GDC project identifier
  • Network access to api.gdc.cancer.gov
Expected outputs
  • Per-field coverage table separating populated from informative values
  • Assay coverage as a percentage of the cohort
  • A yes/no verdict for six common analysis classes
  • A chart contrasting populated with informative coverage, field by field
Steps
  1. Fetch project summary and per-assay case counts
  2. Request facet counts for the clinical fields that gate common analyses
  3. Separate absent fields from fields populated with non-answers
  4. Flag one-to-many fields where per-case percentages cannot be inferred
  5. Retrieve case-level fields and test whether a survival endpoint is derivable
  6. Print a verdict for each analysis class

Start here

Starter code generated from this record’s own identifiers, then the access steps.

Get the data in code

GDC: list open files and download thempython

Open-access files need no account. Controlled files need an approved dbGaP request and a token passed to gdc-client.

import json, requests

PROJECT = "WCDT-MCRPC"
filters = {"op": "and", "content": [
    {"op": "in", "content": {"field": "cases.project.project_id", "value": [PROJECT]}},
    {"op": "in", "content": {"field": "access", "value": ["open"]}},
]}
params = {"filters": json.dumps(filters),
          "fields": "file_id,file_name,data_category,data_type,file_size",
          "size": "10000", "format": "JSON"}
files = requests.get("https://api.gdc.cancer.gov/files", params=params, timeout=60).json()["data"]["hits"]
print(len(files), "open files")

# Write a manifest and fetch with the GDC client (https://gdc.cancer.gov/access-data/gdc-data-transfer-tool)
with open("manifest.txt", "w") as fh:
    fh.write("id\n" + "\n".join(f["file_id"] for f in files))
# $ gdc-client download -m manifest.txt
GDC: clinical table for every casepython
import json, requests

filters = {"op": "in", "content": {"field": "project.project_id", "value": ["WCDT-MCRPC"]}}
params = {"filters": json.dumps(filters), "size": "5000", "format": "TSV",
          "fields": ",".join([
              "submitter_id", "demographic.vital_status", "demographic.days_to_death",
              "diagnoses.days_to_last_follow_up", "diagnoses.ajcc_pathologic_stage",
              "diagnoses.treatments.treatment_type", "diagnoses.treatments.treatment_outcome"])}
tsv = requests.get("https://api.gdc.cancer.gov/cases", params=params, timeout=60).text
open("WCDT-MCRPC_clinical.tsv", "w").write(tsv)
This page as data: limitations firstbash
curl -s https://cd2s.vercel.app/data/datasets/gdc-wcdt-mcrpc.json | python3 -c '
import json, sys
r = json.load(sys.stdin)
for l in r["limitations"]:
    print(l["severity"].upper(), "-", l["statement"][:120])
print("survival endpoint:", r["longitudinal"]["has_survival_endpoint"], "| treatment response:", r["longitudinal"]["has_treatment_response"])'

Access steps

  1. 1
    Read the PNAS marker paper for the clinical annotationFor people1-2 hours

    It carries the outcome and treatment context that the harmonized records lack. Decide from it whether your question is viable.

    https://pubmed.ncbi.nlm.nih.gov/31061129/
  2. 2
    Scope with the 200 open-access filesFor people1 hour
    https://portal.gdc.cancer.gov/projects/WCDT-MCRPC
  3. 3
    Submit a dbGaP data access requestFor peopledays to a few weeks

    Requires: eRA Commons account, institutional signing official approval

    https://gdc.cancer.gov/access-data/obtaining-access-controlled-data
  4. 4
    Query the project from code, with no credentialsFor agents

    The file index is public even where files are not, so an agent can size the cohort before anyone requests access.

    curl -s 'https://api.gdc.cancer.gov/files' --get \
      --data-urlencode 'filters={"op":"in","content":{"field":"cases.project.project_id","value":["WCDT-MCRPC"]}}' \
      --data-urlencode 'fields=file_id,file_name,data_type' \
      --data-urlencode 'size=10000' --data-urlencode 'format=TSV'
    https://docs.gdc.cancer.gov/API/Users_Guide/Getting_Started/

    Generated from repository policy. Check the linked policy before downloading.

  5. 5
    Pass the token when the agent needs controlled filesFor agents

    Without a token, an API query may return only the open subset. Compare returned counts with the record before treating them as the whole cohort.

    Requires: GDC authentication token

    curl -H "X-Auth-Token: $GDC_TOKEN" https://api.gdc.cancer.gov/data/<file_id>
    https://docs.gdc.cancer.gov/API/Users_Guide/Getting_Started/

    Generated from repository policy. Check the linked policy before downloading.

Provenance

All of it, and more, is in this record’s JSON.

Identifiers

Versions and verification

Released
1 Jan 2019
Metadata retrieved
18 Sept 2026
Review status
Project-curatedCD2S project curation on 18 Sept 2026
Data generation funding
Funded data generation
Open questions from review
  • The PNAS marker paper reports clinical outcomes for this cohort, but vital status is "unknown" for all 101 cases in the GDC harmonized records. Confirm whether outcome data are obtainable from the supplementary material or only under dbGaP terms.

Funding

Awards resolved through NIH RePORTER. Awards that paid to generate these data are listed apart from awards that paid to reuse them. Both are returns on NCI investment, but different ones.

Funded data generation

  • P50CA092629Project 2: Overcoming Microenvironment-Mediated Resistance to AR Pathway Inhibition in High-Risk Prostate CancerBrett Stewart Carver, Yu ChenFY2001-2026API2
  • P30CA008748Cancer Center AdministrationALEX MACDONALD, SELWYN M VICKERSFY1985-2026API2
  • P50CA186786Michigan Prostate SPORE 2025-2030ARUL M CHINNAIYAN, Ganesh S PalapattuFY2014-2026API2
  • P50CA090381Gleason-based mRNA and Metabolomic Profiling to Predict Prostate Cancer ProgressMassimo Loda, Steven P. BalkFY2003-2017API2
  • U54CA224079Project 2: Reversing resistance caused by lineage plasticity through epigenetic therapyYu Chen, CHARLES L. SAWYERSFY2017-2021API2
  • P50CA211024Project 1: Non-Invasive Clinical Assay for Early Detection of Treatment Resistance in Patients with Metastatic Prostate CancerHimisha Beltran, David S. RickmanFY2017-2021API2
  • P50CA097186Project 2: Understanding and Targeting the Lineage plasticity in the Genomic Umbrella Neoadjuvant Study (GUNS)Martin Edwin Gleave, RUTH D ETZIONIFY2002-2026API2
  • R01CA155169Understanding Resistance to Next Generation AntiandrogensCHARLES L. SAWYERSFY2012-2022API
  • R01CA125612Towards Understanding Prostate Cancer HeterogeneityMARK A. RUBINFY2007-2017API

Funded reuse of these data

  • R35CA197566Mechanisms governing metastatic dormancy and reactivationFILIPPO G GIANCOTTIFY2016-2022API
  • R00CA194289MDSC-Tumor Crosstalk in Prostate Cancer Progression and Castration ResistanceGuocan WangFY2018-2020API
  • T32CA108462Molecular and Cellular Mechanisms in CancerANDREI GOGA, ZENA WERBFY2004-2024API
  • R01CA251245Targeting Prostate Cancer Lineage Plasticity with BET Bromodomain InhibitionJoshi James AlumkalFY2020-2024API
  • R01CA230516DNA repair alterations in metastatic prostate cancer: functional and therapeutic implicationsAlan Ashworth, Felix Yi-Chung FengFY2018-2022API
  • R01CA227025Molecular Mechanisms of Castration Resistant Prostate Cancer Recurrence & Therapeutic StrategiesFelix Yi-Chung Feng, Nupam P MahajanFY2019-2023API
  • R01CA251555Elucidation of the genetic mechanisms driving prostate tumorigenesis through integrative computational and functional approachesMATTHEW L FREEDMAN, Bogdan PasaniucFY2021-2025API
  • R01CA193910Defining the epigenetic landscape in human prostate cancerMYLES A BROWN, MATTHEW L FREEDMANFY2015-2019API
  • R00CA135592Androgen Receptor Regulation by PhosphorylationShaoyong ChenFY2011-2013API
  • K99CA135592Androgen Receptor Regulation by PhosphorylationShaoyong ChenFY2008-2009API

and 13 more

Funded infrastructure or harmonization

  • P50CA140388Administrative Supplement to MD Anderson Cancer Center Prostate Cancer SPOREChristopher J. Logothetis, Timothy Charles ThompsonFY2009-2022API
  • P30CA016672The University of Texas MD Anderson Cancer Center Support Grant (CCSG)PETER W PISTERS, Vicki HuffFY1985-2026API
  • P01CA094060TGF&, PI3K and HER2 Pathways in Breast Cancer MetastasisJOAN MASSAGUE, SCOTT W. LOWEFY2002-2018API
  • P30CA093373Integrated Cancer Biology ProgramWolf-Dietrich Heyer, KIT S LAMFY2002-2026API
  • P30CA082103Leadership, Planning and EvaluationAlan Ashworth, Charles Scott CraikFY1999-2026API
  • U54CA156732The University of Massachusetts, Boston - Dana-Farber/Harvard Cancer Center U54 Comprehensive Partnership for Cancer Disparities ResearchGregory Alan Abel, KASISOMAYAJULA VISWANATHFY2010-2026API
  • P01CA163227Androgen Receptor Action in Castration Resistant Prostate CancerSteven P. Balk, PETER S NELSONFY2013-2026API
  • U01CA268933Microfluidic isolation and molecular analysis of circulating tumor cells for the study of neuroendocrine transdifferentiation in prostate cancerMelissa Abel, Mehmet TonerFY2022-2026API
  • U01CA224044Patient-Derived Models of Prostate Cancer for Personalized MedicineYu Chen, PHILLIP ANDREW FUTREALFY2019-2023API
  • P30CA015704Prostate CancerPETER S NELSON, Marion Shonn DorerFY1985-2026API

and 3 more

For softwarerecord JSON